Pharma's Almanac

37 Articles Available

0 2

Commitment to ESG Principles

How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?

PAO-03-24-CL-03

Accelerating Product Development

What strategies are being employed to accelerate product development and commercialization without compromising quality?

PAO-03-24-CL-02

CDMO - Small Biotech

Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility

PAO-02-24-CL-07

Tech Transfer

Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies

PAO-02-24-CL-06

Roundtable

What do you see as the most significant regulatory decision or guidance on the horizon for 2024 (or beyond)?

PAO-12-23-RT-02

Roundtable

What Do You Think Was The Single Most Consequential Event Or Result In Pharma/Biopharma In 2023?

PAO-12-23-RT-01

Real-World Data

How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future?

PAO-09-23-RT-01

Industry Wisdom

What Piece of Conventional Industry Wisdom Do You Think is Misguided, Outdated, or Just Plain Wrong?

PAO-09-23-RT-02

International Markets

In what international markets do you anticipate significant developments in the near future?

PAO-01-23-RT-02

Disruptive Technology

What do you view as the most disruptive or transformational technology or development on the horizon?

PAO-01-23-RT-01

Unmet Needs

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

PAO-06-022--RT-01

Industry Challenges

What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

O-06-022--RT-01

Immuno-Oncology

Tuning the Myeloid Compartment with a Best-in-Class CDMO

PAO-06-022-CL-04

Leadership

Q: What’s the key to being a leader in the industry?

PAO-03-022-RT-02

Milestones

Q: What important company milestone do you anticipate reaching in 2022?

PAO-03-022-RT-01

Automation

Innovating in Automation and Data Management to Advance Microbiology

PAO-03-22-R250-06

Drug Development

Advancing Drug Development with Emerging Technologies

PAO-02-22-R250-03

Personalized and Precision Medicine

Q: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?

PAO-12-21-RT-01

Therapeutic Progress

Q: For what therapeutic area do you think we will see the greatest progress in the coming years?

PAO-12-21-RT-02

Bispecific Antibodies

A Small Biotech with Two Complex Bispecific Antibody Candidates Benefits from Lonza’s Blend of Expertise and Flexibility

PAO-12-21-CL-01

Biotech-CDMO Relationship

For mAbs, a Small Biotech Recognizes the Value in Lonza’s Expertise and Track Record

PAO-09-21-CL-03

Biotech-CDMO Relationship

Illustrating a Successful Small Biotech-CDMO Relationship

PAO-08-21-CL-03

Vaccine Collaboration

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine Against Novel Coronavirus

PR-M05-20-NI-001

3D Bioprinting

Lonza and Allevi Collaborate to Advance 3D Bioprinting

PR-M01-20-NI-012

0 2

Lonza

37 Articles Available

Can't find what you're looking for? Try our advanced search.

Commitment to ESG Principles

How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?

Accelerating Product Development

What strategies are being employed to accelerate product development and commercialization without compromising quality?

CDMO - Small Biotech

Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility

Tech Transfer

Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies

Roundtable

What do you see as the most significant regulatory decision or guidance on the horizon for 2024 (or beyond)?

Roundtable

What Do You Think Was The Single Most Consequential Event Or Result In Pharma/Biopharma In 2023?

Real-World Data

How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future?

Industry Wisdom

What Piece of Conventional Industry Wisdom Do You Think is Misguided, Outdated, or Just Plain Wrong?

International Markets

In what international markets do you anticipate significant developments in the near future?

Disruptive Technology

What do you view as the most disruptive or transformational technology or development on the horizon?

Unmet Needs

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

Industry Challenges

What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

Immuno-Oncology

Tuning the Myeloid Compartment with a Best-in-Class CDMO

Leadership

Q: What’s the key to being a leader in the industry?

Milestones

Q: What important company milestone do you anticipate reaching in 2022?

Automation

Innovating in Automation and Data Management to Advance Microbiology

Drug Development

Advancing Drug Development with Emerging Technologies

Personalized and Precision Medicine

Q: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?

Therapeutic Progress

Q: For what therapeutic area do you think we will see the greatest progress in the coming years?

Bispecific Antibodies

A Small Biotech with Two Complex Bispecific Antibody Candidates Benefits from Lonza’s Blend of Expertise and Flexibility

Biotech-CDMO Relationship

For mAbs, a Small Biotech Recognizes the Value in Lonza’s Expertise and Track Record

Biotech-CDMO Relationship

Illustrating a Successful Small Biotech-CDMO Relationship

Vaccine Collaboration

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine Against Novel Coronavirus

3D Bioprinting

Lonza and Allevi Collaborate to Advance 3D Bioprinting